https://www.selleckchem.com/pr....oducts/vorapaxar.htm
Vortioxetine significantly improved mood in MDD+AUD patients (P.001), with no differences when compared to MDD (P=.36). A substantial rate (45.6%) of comorbid subjects obtained clinical remission at endpoint (P=.36 vs MDD). We additionally observed baseline to endpoint improvements on all secondary outcomes (P.001), with no significant difference between groups. Overall, vortioxetine was safe and well tolerated. Given its effectiveness on mood, cognition, and functioning, its good safety and tolerability profile, and low poten
Like
Comment
Share
